Fierce Pharma
AUGUST 26, 2024
Restructuring seems to be the name of the game for many large drugmakers these days, and Belgium-based UCB is no except | Belgium’s UCB is selling off its mature neurology and allergy business—plus a manufacturing plant—in mainland China. The deal will see local healthcare asset manager CBC Group and Abu Dhabi-based investment firm Mubadala pay UCB $680 million.
MedCity News
AUGUST 26, 2024
With so much hinging on technology that is the subject of so much hype, it is important to understand where AI actually helps at present — and where it most definitely does not. The post The Truth About AI and Healthcare Payer Modernization appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 26, 2024
Even as Johnson & Johnson prepares to weather the impact of negotiated Medicare drug prices on two of its | The new rebate model would require eligible hospitals to submit rebate claims after paying full price for the drugs, as opposed to upfront discounts.
MedCity News
AUGUST 26, 2024
Automation startup Qventus launched a new AI assistant designed to alleviate healthcare staff’s administrative burden by completing mundane tasks for them. The assistant was built in collaboration with health systems, including Northwestern Medicine, Ardent Health and Allina Health. The post Why Northwestern Is Using Qventus’ New AI Assistant appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 26, 2024
When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. | Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.
MedCity News
AUGUST 26, 2024
What if we placed the needs of the most vulnerable at the heart of healthcare innovation? This isn’t simply about equity; it’s about unleashing a wave of creativity that could transform healthcare for everyone. The post Trickle-up Innovation: The Unexpected Benefits of Designing Healthcare from the Bottom Up appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
AUGUST 26, 2024
A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals in the controversial 340B programme
Fierce Pharma
AUGUST 26, 2024
Five months after the FDA rejected Regeneron’s bid for acc | Five months after the FDA rejected Regeneron’s bid for accelerated approval of its T-cell engager odronextamab because of the immaturity of its confirmatory trial, the European Union has signed off on the treatment for two types of blood cancers. The European Commission also approved SIFI's first-of-its-kind Akantior for a rare corneal infection disorder.
PharmaTech
AUGUST 26, 2024
In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.
Fierce Pharma
AUGUST 26, 2024
In this week's episode of "The Top Line," we look at factors driving the continuing decli | In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.
MedCity News
AUGUST 26, 2024
Waltz Health launched Waltz Connect on Monday. The solution supports payers and aims to lower specialty drug costs. The post Waltz Health Unveils New Solution to Lower Specialty Medication Costs appeared first on MedCity News.
PharmaTech
AUGUST 26, 2024
Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.
Healthcare Success
AUGUST 26, 2024
The healthcare industry is under immense pressure to produce content quickly. Generative AI might seem like a quick fix, but the industry’s specific challenges often get in the way. Learn how to streamline your content creation process without sacrificing quality or compliance. Here are our best tips: Prioritize Performance Analytics Determining the effectiveness of content quickly and accurately is challenging, so it’s important to build the right team or partner with the right agency.
ALULA
AUGUST 26, 2024
As a leader, your days are jam-packed —meetings, emails, putting out fires, rinse and repeat. It's enough to make your head spin. With all the demands on your time, it can be tempting to skip over those daily check-ins with your team. But trust us, that would be a costly mistake.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
PM360
AUGUST 26, 2024
*This is a reprint of the MIT Sloan Career Development Office website article.* Fortune 500s or Start-Ups; what are the opportunities and challenges for top school business graduates to consider for the Healthcare/Pharma/Biotech vertical? An MIT Sloan Career Development Office Q&A with Jay Galeota, President and CEO of Kallyope. Q: After consulting (33.7%), technology (24.1%) and finance(19.9%), your vertical secured the next highest percentage of MIT Sloan’s class of 2023 gradates (5.8
Pharmaceutical Commerce
AUGUST 26, 2024
Chris Williams expands on the services that a third-party logistics (3PL) partner should offer, while sharing ways to alleviate standard supply chain issues.
pharmaphorum
AUGUST 26, 2024
Siemens Healthineers has agreed a $224m deal to buy the diagnostic arm of Novartis' AAA radiopharmaceuticals unit
Pharmaceutical Technology
AUGUST 26, 2024
Winrevair is the first approved actin signaling pathway-targeting therapy for the treatment of the rare blood vessel disorder.
PharmaVoice
AUGUST 26, 2024
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
Pharmaceutical Technology
AUGUST 26, 2024
The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.
PharmaVoice
AUGUST 26, 2024
The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.
PharmExec
AUGUST 26, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
AUGUST 26, 2024
Invenra received rare pediatric disease designation (RPDD) and orphan drug designation (ODD) from the FDA for INV724 to treat neuroblastoma.
PharmExec
AUGUST 26, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
AUGUST 26, 2024
The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.
PharmExec
AUGUST 26, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmacy Times
AUGUST 26, 2024
Aligning with previous data, the drug combination was modestly effective in patients with large B-cell lymphoma pre- and post-CAR-T-cell therapy.
PharmExec
AUGUST 26, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
AUGUST 26, 2024
China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).
PharmExec
AUGUST 26, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
278 
Let's personalize your content